Review: aging hallmarks in AMD, glaucoma and diabetic retinopathy
This abstract reviews how four hallmarks of aging form an interacting network in age-related eye diseases, with different hallmarks dominating in different tissues, and evaluates emerging therapies aimed at these mechanisms. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract says current treatments for age-related eye diseases manage clinical manifestations but do not halt the molecular processes driving progression. [1]
The abstract describes four hallmarks of aging as forming an interactive, self-reinforcing network rather than acting independently. [1]
The abstract states that the same aging mechanisms, routed through distinct tissue contexts, produce divergent clinical phenotypes. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- People with age-related eye diseases such as AMD, glaucoma and diabetic retinopathy, as discussed in a review.
- Summary based on
- Study abstract
- Original publication
- July 1, 2026
Four aging hallmarks linked to age-related eye disease
The abstract states that age-related eye diseases, including age-related macular degeneration (AMD), glaucoma and diabetic retinopathy, are leading causes of permanent blindness. Current treatments manage clinical manifestations but do not halt the molecular processes driving disease progression. Attention has therefore shifted to geroscience, which targets the fundamental biology of aging rather than treating each disease in isolation. Four hallmarks of aging are described as widely implicated: mitochondrial dysfunction, loss of proteostasis, cellular senescence and epigenetic drift. The authors review evidence that these hallmarks do not act independently but form an interactive, self-reinforcing network.
Supporting source [1]
Tissue context routes the network to different diseases
The abstract reports that the way this network engages differs from tissue to tissue. In the high-energy environment of the retinal pigment epithelium, mitochondrial dysfunction is said to dominate and drive AMD. In the mechanically stressed trabecular meshwork, senescence and epigenetic drift are said to take precedence, leading to glaucoma. In the neurovascular unit, chronic hyperglycemia is said to route the same network into a metabolic-epigenetic amplification loop that sustains diabetic retinopathy. The same aging mechanisms, routed through distinct tissue contexts, thus produce divergent clinical phenotypes.
Supporting source [1]
Emerging therapies and intervention nodes under evaluation
The abstract states that the authors also evaluate emerging therapies, including senolytics, mitochondria-targeted agents and partial epigenetic reprogramming. They identify key intervention nodes such as NLRP3, p62 and NAD⁺ metabolism. Dismantling these pathological feedback loops is described as a path beyond symptom management toward combination strategies that restore tissue resilience. The abstract does not report trial results, effect sizes or safety data for these approaches.
Supporting source [1]
How to interpret this
This is an abstract only; the full text was not reviewed. No study design, sample, follow-up, effect sizes or safety data are reported, and the therapies discussed are evaluated in a review, not shown to work in patients.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zong Y, Fan Q, Qiu S, Zhang H, Cen Z. · europepmc.org · July 1, 2026